


First Quarter 2026 Earnings

revvity

May 5, 2026



Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded [hyperlink](#) and is available on the "Financial Information" section of our website at www.revivity.com.

Key Takeaways

Innovation

Introduction of **Signals BioDesign** software for biologics development

Launch of new flagship **Opera Phenix OptIQ** HCS system

Market

Encouraging signs from **Pharma/Biotech** and **Academic/Gov't**

Strong **Diagnostic** trends outside of China

Performance

Organic growth, adj. operating margin, and adj. **EPS above expectations**

Plan to **divest** China ImmunoDx


*A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges
From Discovery to Development, and Diagnosis to Cure*

1Q26 Revenue Highlights




Segments

● Diagnostics ● Life Sciences




Geographic

● AMERICAS ● APAC ● EU



Product Mix

● Recurring ● Non-recurring




1Q26 Financial Results

REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
\$711M	23.6%	\$1.06	\$115M
↑ +7% y/y	↓ -200bps y/y	↑ +4% y/y	
Organic: +3% M&A: +1% FX: +3%	Adj. Gross Margin: 59.5% -220bps y/y	Adj. Tax Rate: 18.3%	YTD FCF % Adj. NI: 97%
		Adj. Net Interest & Other: \$23M	

Life Sciences


● LIFE SCIENCE SOLUTIONS ● SOFTWARE



REVENUE	AJUSTED OP MARGINS
+3% Organic Growth	28.7%
Total: +6% M&A: +2% FX: +2%	-230bps y/y

- +LSD Pharma/Biotech, +MSD Academic/Gov't
- +LSD Life Science Solutions, growth in both reagents and instruments
- +MSD software driven by strong SaaS growth partially offset by renewal timing
- Margin pressure yr/yr driven by investments, extra week and product mix

Diagnostics





REVENUE	AJUSTED OP MARGINS
+4% Organic Growth	21.8%
Total: +8% M&A: 0% FX: +4%	-100 bps y/y

- -LSD ImmunoDx globally, +MSD ImmunoDx ex. China
- +DD Reproductive Health with strength in newborn, strategic partnerships
- Margin pressure yr/yr driven by tariffs, FX, and extra week

2026 Pro Forma* Financial Guidance

REVENUE	\$2.81B - \$2.84B
	Total: 4% to 5%
	Organic: 3% to 4%
	FX: +0.5%, M&A: +0.75%
ADJUSTED OP. MARGIN	28.4%
ADJUSTED EPS	\$5.20 - \$5.30
	Adj. net interest expense, other: ~\$90M
	Adj. tax rate: ~18%
	Average diluted share count: ~112M





Revvity.com